| Revenue Growth | Total revenue 15%; Testing revenue 15%; Afirma 19%; Decipher prostate 12%. |
|---|---|
| Mgmt Confidence | Confident in long-term 80% share but resetting near-term volume expectations lower. |
| Demand Visibility | Decipher volume 1,000 tests lower than expected; Afirma sequential Q3 record. |
| Margin Trends | Non-GAAP Gross Margin 73.7%; Adjusted EBITDA 27.2% exceeding 25% target. |
| Op. Leverage | Moving software costs to R&D; 2027 EBITDA guided lower at 22%. |
| Pricing Power | Normalized ASP rose 2% to $2,900; sustained pricing gains from operations. |
| Vol vs Price | Volume-led 15% growth; ASP contributed 1% including prior period collections. |
| Segment Growth | Afirma outperformed; Decipher prostate volume growth moderated to 12% year-over-year. |
| New Clients | Served one millionth patient; adding new and reactivated physicians in October. |
| Capex & Debt | $150M cash payment for Convergent Genomics; $100M share repurchase program authorized. |
| Regulatory | Medicare reimbursement secured for ProSigna in post-menopausal women with 0-3 nodes. |
| Commentary | Resetting annual Decipher volume growth to 12,000-15,000 tests as a floor. |
| New Launches | Launched ProSigna LDT for breast cancer and TrueMRD for bladder cancer. |
Growth
Q3 revenue grew 15% to $151.8M; Afirma grew 19%, while Decipher prostate grew 12%.
Outlook
FY2027 revenue growth guided to mid-single digits; Decipher volume floor set at 12,000.
Risks
Management pivoted on Decipher volume shortfall, citing 'temporal acceleration' and competition from digital pathology AI.
The company's earnings call, NASDAQ: VCYT, and its 8-K filed with the SEC. Summary written with AI assistance from the call.
Earnings call webcast ↗ Watch on YouTube ↗
Veracyte, Inc.: key numbers
- Share price
- $24.01Close, Nov 16
- Market cap
- $1.94B
- Shares outstanding
- 80.7MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Medical LaboratoriesSIC 8071
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Veracyte, Inc.
All →Veracyte Financial Results
Veracyte reported Q3 2026 financial results with total revenue growing 15% year-over-year to $151.8 million, driven by strong performance in its Afirma and Decipher Prostate tests. The company also announced that its Board of Directors authorized a new $100 million share repurchase program to be executed over a one-year period.
“We delivered solid third quarter results supported by strong profitability and cash generation. Afirma outperformed, while Decipher Prostate volume was below our expectations. We remain confident in the long-term outlook of our business and expect a number of evidence-based catalysts to support growth in our core franchises while also advancing our breast and bladder strategies. As we execute on these opportunities, our differentiated financial profile enables us to continue investing in the business to drive long-term growth.”
Marc Stapley, chief executive officer of Veracyte
Veracyte Insider Jens Holstein Sells $728K of Stock
Jens Holstein sold 15,000 shares of Veracyte, Inc. at $47.00 to $50.00 a share (average $48.50) in 2 transactions, worth $728K in total between Sep 24, 2026 and Oct 27, 2026. Shares held after the trade: 27,471 (-21.4%).
- Value
- $728K
- Shares
- 15,000
- Average price
- $48.50
- Holding change
- -21.4%
- Trade date
- Sep 24, 2026 to Oct 27, 2026
Veracyte Insider Karin Eastham Sells $743K of Stock
Karin Eastham sold 14,850 shares of Veracyte, Inc. at $50.00 a share, worth $743K in total on Oct 27, 2026. Shares held after the trade: 10,247 (-59.2%).
- Value
- $743K
- Shares
- 14,850
- Price
- $50.00
- Holding change
- -59.2%
- Trade date
- Oct 27, 2026
Veracyte Insider Muna Bhanji Sells $81.5K of Stock
Muna Bhanji sold 1,864 shares of Veracyte, Inc. at $43.70 a share, worth $81.5K in total on Oct 19, 2026. Shares held after the trade: 40,854 (-4.4%).
- Value
- $81.5K
- Shares
- 1,864
- Price
- $43.70
- Holding change
- -4.4%
- Trade date
- Oct 19, 2026
Veracyte Insider Jens Holstein Sells $205K of Stock
Jens Holstein sold 5,000 shares of Veracyte, Inc. at $40.95 a share, worth $205K in total on Sep 14, 2026. Shares held after the trade: 27,471 (-15.4%).
- Value
- $205K
- Shares
- 5,000
- Price
- $40.95
- Holding change
- -15.4%
- Trade date
- Sep 14, 2026
Veracyte Signs $150M M&A Deal with Convergent Genomics Inc.
Veracyte completed the acquisition of Convergent Genomics, a genomic diagnostics company focused on bladder cancer, for $150 million in upfront cash plus up to $30 million in milestone-based payments. The deal adds the UroAmp urinary tumor DNA (utDNA) technology to Veracyte's urology portfolio, with a commercial launch expected in late 2028.
- Value
- $150M
- Counterparty
- Convergent Genomics Inc.
“UroAmp brings a differentiated urine-based platform that is especially well suited to non-muscle-invasive disease. Together with our Decipher Bladder and TrueMRD tests, this acquisition strengthens Veracyte’s ability to deliver complementary insights from urine, tissue, and blood to help guide care across the bladder cancer continuum.”
Marc Stapley, Veracyte’s chief executive officer
“We believe this combination can help accelerate the development of new tools that give physicians greater confidence in treatment and monitoring decisions and can ultimately improve care for people living with bladder cancer.”
Brian Slingerland, chief executive officer, Convergent Genomics